Nucleic acid molecules encoding rage fusion proteins

US8344120B2 · kind B2 · utility

Assignee

• TransTech Pharma, LLC · US

Inventors

• Adnan M. M. Mjalli · Oak Ridge, US
• Robert Rothlein · Greenville, US
• Ye Tian · Bloomington, US
• Jeffrey C. Webster · Pleasant Grove, US

Key dates

• Filing date: Jun 13, 2011
• Grant date: Jan 1, 2013
• Expiry date: Jun 13, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin CH2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.